Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma-Reference-Cited by-同舟云学术

Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma

Published:2017-12-21 Issue:25 Volume:130 Page:2709-2717
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Pro Barbara¹,Advani Ranjana²,Brice Pauline³,Bartlett Nancy L.⁴,Rosenblatt Joseph D.⁵,Illidge Tim⁶,Matous Jeffrey⁷,Ramchandren Radhakrishnan⁸,Fanale Michelle⁹,Connors Joseph M.¹⁰,Fenton Keenan¹¹,Huebner Dirk¹²,Pinelli Juan M.¹¹,Kennedy Dana A.¹¹,Shustov Andrei¹³

Affiliation:

1. Robert H. Lurie Comprehensive Cancer Center, Chicago, IL;

2. Division of Oncology, Stanford University Medical Center, Palo Alto, CA;

3. Hemato-oncology Department, Hospital Saint-Louis, Paris, France;

4. Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO;

5. Division of Hematology-Oncology, Department of Medicine, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL;

6. Christie Hospital National Health Service, Manchester, United Kingdom;

7. Colorado Blood and Cancer Institute, Denver, CO;

8. Karmanos Cancer Institute, Detroit, MI;

9. Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX;

10. British Columbia Cancer Agency Centre for Lymphoid Cancer, Vancouver, BC, Canada;

11. Seattle Genetics, Inc, Bothell, WA;

12. Millennium Pharmaceuticals, Inc, Cambridge, MA, a wholly owned subsidiary of Takeda Pharmaceuticals Limited; and

13. Division of Hematology, University of Washington School of Medicine, Seattle, WA

Abstract

Key Points Patients with R/R ALCL who achieved CR with brentuximab vedotin had 79% OS and 57% PFS at 5 years, with median response duration not reached. An estimated 91% of patients who experienced peripheral neuropathy with brentuximab vedotin reported resolution or improvement of symptoms.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/130/25/2709/1404346/blood780049.pdf

Reference19 articles.

1. ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project;Savage;Blood,2008

2. Survival of patients with peripheral T-cell lymphoma after first relapse or progression: spectrum of disease and rare long-term survivors;Mak;J Clin Oncol,2013

3. Autologous stem cell transplantation for T and null cell CD30-positive anaplastic large cell lymphoma: analysis of 64 adult and paediatric cases reported to the European Group for Blood and Marrow Transplantation (EBMT);Fanin;Bone Marrow Transplant,1999

4. Hematopoietic cell transplantation for systemic mature T-cell non-Hodgkin lymphoma;Smith;J Clin Oncol,2013

5. Graft-versus-lymphoma effect for aggressive T-cell lymphomas in adults: a study by the Société Francaise de Greffe de Moëlle et de Thérapie Cellulaire;Le Gouill;J Clin Oncol,2008

Cited by 186 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Peripheral T-cell lymphoma: From biology to practice to the future;Cancer Treatment Reviews;2024-09

2. Dermatologic toxicities of antibody-drug conjugates;Journal of the American Academy of Dermatology;2024-08

3. Treatment strategies and outcome in relapsed peripheral T-cell lymphoma: results from the Netherlands Cancer Registry;Blood Advances;2024-07-10

4. Novel clinical risk stratification and treatment strategies in relapsed/refractory peripheral T-cell lymphoma;Journal of Hematology & Oncology;2024-06-01

5. Antibody–drug conjugates in the treatment of lymphoid neoplasms;memo - Magazine of European Medical Oncology;2024-05